Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month
Details for all three investor conferences are as follows:
39th Annual
Date: |
|
|
Time: |
|
|
Webcast: |
Audio-only Link to Webcast Here |
2021
Date: |
|
|
Time: |
Management available for 1x1 meetings |
H.C. Wainwright BioConnect 2021 Conference - Corporate Presentation
Date: |
|
The session time is on-demand, beginning
To register and view the presentation, please click here.
A replay for all conferences will be available on the Events and Presentations section investor section of the
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of
Abraxane® is a registered trademark of
Avastin® is a registered trademark of
Doxil® is a registered trademark of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005217/en/
617-775-5956
Source: